LeonaBio (LONA) investor relations material

Strategic update and clinical development overview

• Licensed rights to lasofoxifene, a late-stage asset for metastatic breast cancer, diversifying the pipeline and prompting a rebrand focused on innovation and patient impact.

• Lasofoxifene targets ER-positive, HER2-negative metastatic breast cancer, especially in patients with ESR1 mutations, a key resistance mechanism after standard therapies.

• The breast cancer market is large and growing, with significant unmet need for differentiated therapies, especially in the $5B+ U.S. second-line segment.

• Lasofoxifene's unique receptor modulation and compatibility with combination regimens position it as a strong candidate in this evolving landscape.

Clinical data and trial progress

• Phase II ELAINE 2 trial showed lasofoxifene plus abemaciclib achieved a median PFS of 13 months and a 56% response rate in heavily pretreated patients.

• ELAINE 1 demonstrated lasofoxifene monotherapy outperformed fulvestrant in PFS (5.6 vs. 3.7 months) and showed strong activity against difficult ESR1 mutations.

• Lasofoxifene displayed superior potency against ESR1 mutations compared to other SERDs and SERMs, with favorable tolerability and no significant toxicities observed.

• The ongoing ELAINE 3 phase III trial is enrolling 600 patients with ESR1-mutated disease, comparing lasofoxifene/abemaciclib to fulvestrant/abemaciclib, with PFS as the primary endpoint.

• Enrollment is over halfway complete, with top-line data expected in 2027; the trial design is event-driven.

Expert perspectives and market positioning

• Experts emphasized the need for better oral regimens to delay chemotherapy and improve quality of life for metastatic breast cancer patients.

• Lasofoxifene's tissue-selective profile offers potential benefits in bone and vaginal health, differentiating it from other endocrine therapies.

• Combination strategies, especially with abemaciclib, are seen as critical to overcoming resistance and achieving double-digit PFS in the second-line setting.

• Routine ESR1 mutation testing is now standard, enabling targeted therapy selection and supporting lasofoxifene's market opportunity.

• Experts highlighted lasofoxifene's efficacy across diverse ESR1 mutations, including the challenging Y537S variant, and its potential in polyclonal mutation settings.